Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H15N2O2.Cl |
| Molecular Weight | 182.649 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
| Molecular Formula | C6H15N2O2 |
| Molecular Weight | 147.1955 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date1972 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterisation of acetylcholinesterase release from neuronal cells. | 2013-03-25 |
|
| Antispasmodic effects of eugenol on rat airway smooth muscle. | 2011-12 |
|
| Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). | 2011-09-25 |
|
| TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011-02-18 |
|
| Aggravation of seizure-associated microvascular injuries by ibuprofen may involve multiple pathways. | 2010-12 |
|
| Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010-10 |
|
| Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase. | 2010-09-06 |
|
| Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. | 2010-08 |
|
| The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions. | 2010-06-15 |
|
| Structural and functional effects of developmental exposure to ethanol on the zebrafish heart. | 2010-06 |
|
| Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. | 2010-03 |
|
| Cholinergic responses of ophthalmic arteries in M3 and M5 muscarinic acetylcholine receptor knockout mice. | 2009-10 |
|
| Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. | 2009-08 |
|
| Muscarinic receptors prevent oxidative stress-mediated apoptosis induced by domoic acid in mouse cerebellar granule cells. | 2009-04 |
|
| The cholinomimetic agent carbachol induces headache in healthy subjects. | 2009-02 |
|
| Enhanced proliferation of SNU-407 human colon cancer cells by muscarinic acetylcholine receptors. | 2008-11-30 |
|
| Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. | 2008-09-25 |
|
| Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells. | 2008-07 |
|
| A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. | 2008-04 |
|
| Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells. | 2007-09 |
|
| [Effects of carbachol on apoptosis of intestinal epithelial cells after gut ischemia/reperfusion in rat]. | 2007-08 |
|
| Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. | 2007-05 |
|
| Theoretical and experimental investigation of calcium-contraction coupling in airway smooth muscle. | 2006 |
|
| Regeneration of cardiomyocytes from bone marrow: Use of mesenchymal stem cell for cardiovascular tissue engineering. | 2003-03 |
|
| Studies on the development of tolerance and potential spinal neurotoxicity after chronic intrathecal carbachol-antinociception in the rat. | 1991-02 |
|
| Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. | 1990-11-13 |
|
| Catalepsy induced by carbachol microinjected into the pontine reticular formation of rats. | 1990-07-31 |
|
| Renal function during onset of carbachol-induced hypertension in conscious rats. | 1990 |
|
| Plasma catecholamines and alpha 1-adrenoceptor function in hemodialysis-associated hypotension. | 1990 |
|
| Anatomical analysis of frontal cortex sites at which carbachol induces motor seizures in the rat. | 1988-05 |
|
| The effect of cholinergic stimulation in the nucleus accumbens on locomotor behavior. | 1988-02-16 |
|
| Novel 'soft' anticholinergic agents. | 1988-02 |
|
| Cardiovascular effects of cholinergic agents in the ventral-lateral midbrain periaqueductal gray of the rat. | 1987-12 |
|
| Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. | 1987-03 |
|
| Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse. | 1987 |
|
| Cholinergic induction of seizures in the rat prefrontal cortex. | 1986-06-23 |
|
| Subclassification of muscarinic receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat. Selectivity of some classical agonists. | 1985-12 |
|
| A crucial epileptogenic site in the deep prepiriform cortex. | 1985-10-17 |
|
| Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984-10 |
|
| Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". | 1984-09-03 |
|
| Seizures induced by carbachol, morphine, and leucine-enkephalin: a comparison. | 1983-04 |
|
| Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983-01 |
|
| [Effects of atropine and scopolamine on the aggressive behavior and convulsions induced by carbachol and eserine injected into the cerebral ventricles of the cat]. | 1980 |
|
| Evidence that a nigral gabaergic--cholinergic balance controls posture. | 1979-01-01 |
|
| Muscarine- and carbachol-induced aggressions: fear and irritable kinds of aggressions. | 1977-12-28 |
|
| Midbrain interaction with the hypothalamus in expression of aggressive behavior in cats. | 1977 |
|
| Motor disturbances produced by intrastriatal injection of cyclic AMP and cyclic GMP. | 1976-11 |
|
| Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol. | 1975-02 |
|
| Sustained atrial fibrillation induced by carbachol, methacholine and bethanechol. | 1971-04 |
|
| Avoidance learning: long-lasting deficits after temporal lobe seizure. | 1969-12-12 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27118568
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:17 GMT 2025
by
admin
on
Mon Mar 31 17:49:17 GMT 2025
|
| Record UNII |
8Y164V895Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
NDF-RT |
N0000175884
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5831
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
C47430
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
DB00411
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
32865
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
488
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
298
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
m3051
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
3385
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
51-83-2
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
6373
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
1092009
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
1999
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
Carbachol
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
100000081628
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
200-127-3
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
Carbachol
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||